Vna Northwest, Inc Medicare Approved Location: 607 Bantam Road, Unit F, Bantam, Connecticut 06750 Phone: (860) 567-6000 |
News Archive
​Biochemical sleuthing by an Indiana University graduate student has ended a nearly 50-year-old search to find a megamolecule in bacterial cell walls commonly used as a target for antibiotics, but whose presence had never been identified in the bacterium responsible for the most commonly reported sexually transmitted disease in the United States.
The researchers looked at 871 students (466 girls and 405 boys) for seven years from ages 10 to 18. Each year, they asked the children questions about their involvement in bullying or victimizing behavior, their relationships, and other positive and negative behaviors.
Medical diagnostics company Biomoda, Inc. is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.
GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.
› Verified 6 days ago